Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
The Ministry of Health, Labor and Welfare (MHLW) plans to draw up guidelines that specify prerequisites for target patients and physicians for innovative drugs, a senior MHLW official says - giving shape to a government pledge made in June to…
To read the full story
Related Article
- Chuikyo OKs Plan to Compile “Optimal Use Guidelines,” Beginning with Opdivo, Repatha
July 28, 2016
- MHLW to Canvass Drug Makers’ Opinions on Real-World Roles of “3 Key Officers”: Pharma Safety Head
July 27, 2016
- MHLW Pharma Bureau Chief Wants to Discuss Roles of Drug Makers’ 3 Key Officers
July 15, 2016
- MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
REGULATORY
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…